Mucin Glycans: A Target for Cancer Therapy
Open Access
Abstract
Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major difference between them is that secreted mucins do not have transmembrane structural domains, and the expression of each mucin is organ and cell-specific. Under physiological conditions, mucin glycans are involved in the composition of the mucus barrier and thus protect the body from infection and injury. However, abnormal expression of mucin glycans can lead to the occurrence of diseases, especially cancer, through various mechanisms. Therefore, targeting mucin glycans for the diagnosis and treatment of cancer has always been a promising research direction. Here, we first summarize the main types of glycosylation (O-GalNAc glycosylation and N-glycosylation) on mucins and the mechanisms by which abnormal mucin glycans occur. Next, how abnormal mucin glycans contribute to cancer development is described. Finally, we summarize MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example. In this section, we specifically elaborate on the recent new cancer therapy CAR-M, which may bring new hope to cancer patients.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
- Health Research Project of Shaanxi Province (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
- Scientific Research Projects of Education Department of Shaanxi Provincial Government (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
- Ph.D. start-up fund of Yan’an University (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
- Shaanxi Province Key Science and Technology innovation team (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
- Innovation Team of Yan’an City-Innovation Team for Chronic Disease Prevention and Control (22264023, 82060521, 82260489, 82260530, 2022E019, 22JK0614, YDBK2020-30, YDBK2022-15, 2020TD-039, 2018CXTD-03)
This publication has 211 references indexed in Scilit:
- Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineProceedings of the National Academy of Sciences, 2011
- The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell AdenocarcinomaAnnals of Surgery, 2011
- Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse modelCancer Immunology, Immunotherapy, 2010
- Circulating Galectin-3 Promotes Metastasis by Modifying MUC1 Localization on Cancer Cell SurfaceCancer Research, 2009
- Association of Cell Surface Mucins with Galectin-3 Contributes to the Ocular Surface Epithelial BarrierJournal of Biological Chemistry, 2009
- Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccineBMC Cancer, 2009
- Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine modelBritish Journal of Cancer, 2009
- Regulation of Glycan Structures in Animal TissuesJournal of Biological Chemistry, 2008
- MUC1 Induced by Epstein-Barr Virus Latent Membrane Protein 1 Causes Dissociation of the Cell-Matrix Interaction and Cellular Invasiveness via STAT SignalingJournal of Virology, 2007
- Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functionsEMBO Reports, 2006